Acute (single 50 mg dose, healthy adult, opioid-naive, BZD-naive)

• Onset 1-3 hours oral. Effect builds gradually rather than the sharp onset of a benzodiazepine.
• Anxiolytic — described by users as "calmer baseline" or "less reactive" rather than the dissociative-quality calm of benzodiazepines. The anxiolysis feels more like a smoother emotional response curve than a thick wall between you and your feelings.
• No euphoria — users do not report a "rush" or pleasant subjective high; the absence of abuse liability tracks with this. Single-dose etifoxine is not a recreational compound.
• Minimal sedation — sedation occurs in ~5% of users, particularly at first dose, but is much less common and less pronounced than even low-dose benzodiazepines. Many users report no sedation at all.
• Cognitive profile — preserved alertness, working memory, processing speed, motor coordination. This is the differentiating feature vs benzos, replicated in Nguyen 2006 and consistent with biohacker anecdote.

Chronic (after 2-7 days steady-state, 50 mg TID)

• Sustained anxiolysis as the active metabolite (diethyl-etifoxine, ~20 hr half-life) accumulates and provides smoother day-long coverage than parent compound alone.
• No tolerance development at therapeutic doses over weeks to months in the available clinical-trial duration (4-12 weeks). Whether longer-term (6+ month) use produces tolerance is less well-characterized; French label discourages chronic indefinite use.
• No inter-dose anxiety / rebound between doses — contrast with alprazolam where the short half-life produces inter-dose oscillation. Etifoxine's longer-acting active metabolite smooths trough states.
• Sleep architecture — minimal disruption per the limited published data. Users do not report the REM/SWS suppression characteristic of benzodiazepines.
• Cognitive maintenance — no cumulative cognitive impairment reported in the 4-12 week trial duration. Long-term cognitive data is limited.

Discontinuation (after 4-12 weeks of TID dosing)

• Minimal withdrawal — etifoxine does not produce benzodiazepine-class physiological withdrawal because the receptor profile is different. Most users stop directly with no taper or with a brief 1-2 week step-down without significant rebound symptoms. This is one of the clearest differentiators from benzodiazepines and was the standout finding in Nguyen 2006 (lorazepam group rebound at day 35 vs etifoxine clean discontinuation).
• No documented seizure risk on cessation — unlike benzodiazepines.
• Some users report mild rebound anxiety at discontinuation, but typically resolves within 1-2 weeks without intervention.

• Tolerance buildup: minimal documented at therapeutic doses over 4-12 weeks. Longer-term tolerance is less well-characterized. Mechanism (TSPO + non-BZ GABA-A site + endogenous neurosteroid synthesis) does not predict the rapid α1-mediated tolerance that characterizes benzodiazepines.
• Recommended cycle: French label supports 4-12 weeks per treatment course. Discontinuation between courses is reasonable but not strictly required. No formal "washout" needed.
• Reset protocol: there is no required reset — discontinuation is uneventful in most users.
• Long-term (>1 year) use: poorly characterized. Most clinical experience is in shorter treatment courses for adjustment-disorder anxiety.

Synergistic / compatible

• SSRIs / SNRIs — mechanistically distinct; etifoxine sometimes used as short-term anxiolytic bridge during the 4-8 week SSRI titration window. No documented PK concerns. Compatible.
• L-theanine 200-400 mg — different mechanism (NMDA modulation, GABA bumping, glutamine-transport inhibition); mild additive anxiolysis possible. Compatible.
• Magnesium glycinate — different mechanism (NMDA glycine site, mineral status); compatible with no documented interaction.
• Ashwagandha (KSM-66 or Sensoril) — HPA-axis cortisol normalization; different mechanism, compatible.
• Behavioral / CBT / breathwork — non-pharm anxiolytic; ideal stacking partner.

Avoid stacking with

• Alcohol — additive CNS depression possible despite cleaner monotherapy profile than benzodiazepines. French label advises avoiding alcohol during treatment. Hepatotoxicity signal is amplified by alcohol exposure.
• Benzodiazepines (alprazolam, lorazepam, diazepam, clonazepam) — mechanistically overlapping (both enhance GABA-A tone, though via different binding sites). Not formally contraindicated but rarely justified — the entire rationale for etifoxine is benzodiazepine-sparing.
• Hepatotoxic medications (high-dose acetaminophen, isoniazid, methotrexate, valproate, statins, amiodarone) — additive hepatotoxicity risk given the etifoxine DILI signal.
• Allopregnanolone-active agents (brexanolone, zuranolone, ganaxolone) — etifoxine drives endogenous allopregnanolone synthesis; co-administration with exogenous neurosteroid analogs would produce additive GABA-A neurosteroid-site activation. Not formally studied; theoretical stacking risk for over-sedation.
• Other CNS depressants — first-generation antihistamines (diphenhydramine, hydroxyzine), Z-drugs (zolpidem, zopiclone), opioids, gabapentinoids — additive sedation; compounds lethality risk in combination.
• Phenibut, baclofen, GHB/GBL — GABA-B agonists with their own dependence + withdrawal pharmacology; stacking unjustified.

CYP interactions

• CYP3A4 / CYP2D6 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) — may reduce etifoxine + active-metabolite exposure. Specific data sparse; clinical significance unclear.
• CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice) — may raise etifoxine exposure; conservative dose-adjustment if co-administration is unavoidable.
• CYP2D6 inhibitors / poor-metabolizers — may slow conversion to active metabolite, attenuating effect; or alter parent compound clearance. Not well-characterized.

Specific high-concern combinations

• Etifoxine + alcohol-heavy use — hepatotoxicity signal amplified; CNS depression additive.
• Etifoxine + isoniazid / methotrexate / valproate — additive idiosyncratic-DILI risk.
• Etifoxine + benzodiazepines — redundant mechanism + additive sedation; rarely justified.
• Etifoxine + opioids — additive CNS + respiratory depression. Not as severe as benzo + opioid (no Boxed Warning equivalent), but caution applies.

Other notable

• Hormonal contraception — theoretical interaction via TSPO-mediated steroidogenesis modulation; clinically minor at therapeutic doses.
• Anticoagulants — limited data; no specific PK interaction documented but caution warranted given hepatic metabolism.

• CYP2D6 polymorphisms — likely affect parent compound clearance and possibly active-metabolite formation; specific data sparse.
• CYP3A4 polymorphisms — similar caveat.
• HLA polymorphisms (HLA-B, HLA-DR) — potentially relevant for the immune-mediated cutaneous reactions (DRESS, SJS) by analogy with other DILI/SCAR drugs (e.g., HLA-B57:01 and abacavir, HLA-B15:02 and carbamazepine), but no formal etifoxine-specific HLA association is established.
• For the user's 23andMe data (results pending June 2026): no clinically actionable etifoxine-specific flags expected. CYP2D6 + CYP3A4 polymorphism data would be informational only.

For the user: not sourcing this. Even if a hypothetical anxiety indication emerged, the path would be (a) trial first-line non-Rx options (propranolol PRN, theanine, ashwagandha, behavioral/CBT/breathwork), (b) if those fail, US Rx for buspirone (no etifoxine equivalent in US), (c) only after that ladder is exhausted would EU pharmacy import via genuine prescriber relationship be on the table. Gray-market sourcing for a hepatotoxic-signal-bearing drug is poor risk-reward when first-line options exist.

For users on etifoxine:

• Baseline (before starting): ALT, AST, GGT, ALP, bilirubin (full hepatic panel); CBC; CMP; anxiety scale (HAM-A, GAD-7); subjective sleep-quality baseline; cognitive baseline (CNS Vital Signs, n-back) for "cleaner cognitive profile" verification at 8 weeks.
• At 4 weeks of treatment: repeat ALT, AST (hepatotoxicity-detection window); anxiety scale recheck; subjective tolerability log.
• At 8 weeks: repeat full LFT panel; cognitive-battery recheck.
• At 12 weeks (treatment endpoint): full LFT panel; anxiety scale; subjective rebound-anxiety log on discontinuation.
• Watch flags: ALT/AST >3× ULN → discontinue and recheck; jaundice / dark urine / RUQ pain → STOP immediately + hepatology eval; rash with mucosal/fever/lymphadenopathy → STOP immediately (DRESS/SJS suspicion).

For non-users (this user's current profile): none required. Track the broader TSPO-neurosteroid drug-development frontier (brexanolone, zuranolone, ganaxolone trials in PPD / PMDD / GAD / PTSD) as the field evolves.